Cited 37 times in
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 문찬수 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 정규식 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2016-02-04T10:55:58Z | - |
dc.date.available | 2016-02-04T10:55:58Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0163-2116 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139297 | - |
dc.description.abstract | BACKGROUND: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients METHODS: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC). RESULTS: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017). CONCLUSIONS: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 573~581 | - |
dc.relation.isPartOf | DIGESTIVE DISEASES AND SCIENCES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antiviral Agents/adverse effects | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Carcinoma, Hepatocellular/diagnosis | - |
dc.subject.MESH | Carcinoma, Hepatocellular/epidemiology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/prevention & control* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/virology | - |
dc.subject.MESH | Chi-Square Distribution | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepacivirus/drug effects | - |
dc.subject.MESH | Hepacivirus/genetics | - |
dc.subject.MESH | Hepatitis C, Chronic/complications | - |
dc.subject.MESH | Hepatitis C, Chronic/diagnosis | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Interferon-alpha/adverse effects | - |
dc.subject.MESH | Interferon-alpha/therapeutic use* | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Cirrhosis/diagnosis | - |
dc.subject.MESH | Liver Cirrhosis/epidemiology | - |
dc.subject.MESH | Liver Cirrhosis/prevention & control* | - |
dc.subject.MESH | Liver Cirrhosis/virology | - |
dc.subject.MESH | Liver Neoplasms/diagnosis | - |
dc.subject.MESH | Liver Neoplasms/epidemiology | - |
dc.subject.MESH | Liver Neoplasms/prevention & control* | - |
dc.subject.MESH | Liver Neoplasms/virology | - |
dc.subject.MESH | Logistic Models | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Odds Ratio | - |
dc.subject.MESH | Polyethylene Glycols/adverse effects | - |
dc.subject.MESH | Polyethylene Glycols/therapeutic use* | - |
dc.subject.MESH | Protective Factors | - |
dc.subject.MESH | RNA, Viral/blood | - |
dc.subject.MESH | Recombinant Proteins/adverse effects | - |
dc.subject.MESH | Recombinant Proteins/therapeutic use | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Ribavirin/adverse effects | - |
dc.subject.MESH | Ribavirin/therapeutic use* | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Viral Load | - |
dc.title | Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chansoo Moon | - |
dc.contributor.googleauthor | Kyu Sik Jung | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Oidov Baatarkhuu | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.1007/s10620-014-3361-6 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01389 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03578 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J00737 | - |
dc.identifier.eissn | 1573-2568 | - |
dc.identifier.pmid | 25236421 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs10620-014-3361-6 | - |
dc.subject.keyword | Hepatitis C | - |
dc.subject.keyword | Cirrhosis | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Antiviral therapy | - |
dc.subject.keyword | Sustained virological response | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Moon, Chan Soo | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Jung, Kyu Sik | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Moon, Chan Soo | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Jung, Kyu Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 60 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 573 | - |
dc.citation.endPage | 581 | - |
dc.identifier.bibliographicCitation | DIGESTIVE DISEASES AND SCIENCES, Vol.60(2) : 573-581, 2015 | - |
dc.identifier.rimsid | 45553 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.